TY - JOUR
T1 - Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India
AU - Joshi, Samir
AU - Telang, Rahul
AU - Tambe, Muralidhar
AU - Havaldar, Rajesh
AU - Sane, Manasi
AU - Shaikh, Afshan
AU - Roy, Cherry
AU - Yathati, Kireet
AU - Sonawale, Sanjaykumar
AU - Borkar, Rupalee
AU - Magar, Rahul
AU - Bhitkar, Harshal
AU - Shitole, Satish
AU - Nakate, Leena
AU - Kudrimoti, Jyoti
AU - Mave, Vidya
N1 - Publisher Copyright:
© 2022 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2022/1
Y1 - 2022/1
N2 - We provide an overview of the epidemiology and clinical course of mucormycosis in the coronavirus disease (COVID-19) pandemic era. We conducted a retrospective chart review of 178 patients with clinical or diagnostic, endoscopically or histopathologically confi rmed rhinosino- orbital or cerebral mucormycosis after COVID-19 treatment during the second wave of COVID-19 in Pune, India. Median time to symptom onset from COVID-19 detection was 28 days. Moderate or severe COVID-19 was seen in 73% of patients and diabetes in 74.2%. A total of 52.8% received steroids. Eschar over or inside the nose was seen in 75%, but baseline clinical and laboratory parameters were mostly unremarkable. Bone penetration was present in ≈90% of cases, 30% had soft-tissue swelling of the pterygopalatine fossa and 7% had cavernous sinus thrombosis, and 60% had multifocal mucormycosis. Of the 178 study cases, 151 (85%) underwent surgical debridement. Twenty-six (15%) died, and 16 (62%) of those had multifocal mucormycosis.
AB - We provide an overview of the epidemiology and clinical course of mucormycosis in the coronavirus disease (COVID-19) pandemic era. We conducted a retrospective chart review of 178 patients with clinical or diagnostic, endoscopically or histopathologically confi rmed rhinosino- orbital or cerebral mucormycosis after COVID-19 treatment during the second wave of COVID-19 in Pune, India. Median time to symptom onset from COVID-19 detection was 28 days. Moderate or severe COVID-19 was seen in 73% of patients and diabetes in 74.2%. A total of 52.8% received steroids. Eschar over or inside the nose was seen in 75%, but baseline clinical and laboratory parameters were mostly unremarkable. Bone penetration was present in ≈90% of cases, 30% had soft-tissue swelling of the pterygopalatine fossa and 7% had cavernous sinus thrombosis, and 60% had multifocal mucormycosis. Of the 178 study cases, 151 (85%) underwent surgical debridement. Twenty-six (15%) died, and 16 (62%) of those had multifocal mucormycosis.
UR - http://www.scopus.com/inward/record.url?scp=85121716056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121716056&partnerID=8YFLogxK
U2 - 10.3201/eid2801.211636
DO - 10.3201/eid2801.211636
M3 - Review article
C2 - 34586055
AN - SCOPUS:85121716056
SN - 1080-6040
VL - 28
SP - 1
EP - 8
JO - Emerging infectious diseases
JF - Emerging infectious diseases
IS - 1
ER -